Outcomes measured during the surveillance period included the incidence density rate of CLABSIs (number of cases per 1000 central line-days), CAUTIs (number of cases per 1000 urinary catheter-days) and VAP (number of

cases per 1000 mechanical ventilator-days). DA-HAI rates of VAP, CLABSIs, and CAUTIs per 1000 device-days were calculated by dividing the total number of DA-HAIs by the total number of specific device-days and multiplying the result by 1000 [17]. Device utilization (DU) ratios were calculated by dividing the total number of device-days by the total number of patient-days. Device-days are the total number of days of exposure to the device (central line, ventilator, or urinary catheter) by all of the patients in the selected population during the selected

time period. Patient-days are the total number of days that patients were in the ICU during the selected time Pirfenidone supplier period [17]. EpiInfo® version 6.04b (CDC, Atlanta, GA) and SPSS 16.0 (SPSS Inc., an IBM Company, Chicago, IL) were used to perform the data analyses. Baseline differences among rates were analyzed using the chi-square test for dichotomous variables and a t-test for Regorafenib in vitro continuous variables. Relative risk (RR) ratios, 95% confidence intervals (CIs) and P-values were determined for all outcomes. We recorded 473 patients hospitalized for 2930 days in the RICU. These patients acquired 155 DA-HAIs, with an overall rate of 32.8% (95% CI 28.5–37.2), and 52.9 (95% CI 45.1–61.7) DA-HAIs per 1000 ICU-days. In the PICUs, we recorded 143 patients hospitalized for

1533 days. These patients acquired 35 DA-HAIs, with an overall rate of 24.5% (95% CI 17.7–32.4), and 22.8 (95% CI 15.9–31.6) DA-HAIs per 1000 ICU-days. CLABSIs represented 20% of all HAIs, VAP represented 52%, and CAUTIs represented 28%. The individual characteristics of each ICU, the number of patients enrolled in the study, and the number of ICU-days are shown in Table 1. PICUs collected and sent original data to INICC headquarters, and the Temsirolimus supplier RICU collected and sent aggregated data to the INICC. In the RICU, the device utilization ratio was 0.37 for mechanical ventilation, 0.35 for CLs, and 0.53 for urinary catheters. In the PICUs, the device utilization ratio was 0.37 for mechanical ventilation, 0.59 for CLs, and 0.35 for urinary catheters. Device utilization is shown in Table 1. The total number of HH opportunities observed in the PICUs was 140. The HH compliance rate was 47.1% (95% CI 38.7–55.8). The VAP rate was 31.8 (95% CI 19.9–49.8) per 1000 MV-days in the PICUs and 73.4 (95% CI 58.5–90.6) in the RICU, with an overall rate in the 3 ICUs of 59.0 (95% CI 48.1–71.5) (Table 2). Cultures were performed for VAP patients, and 87.2% showed growth. Klebsiella and methicillin-resistant Staphylococcus aureus (MRSA) were the most common microorganisms associated with VAP, followed by Pseudomonas aeruginosa. The CLABSI rate was 18.8 per 1000 CL-days (95% CI 10.9–29.